Europe Vaccines Market – Industry Trends and Forecast to 2028

Pharmaceutical
Published Report
Feb 2021
Europe
350 Pages
No of Tables: 351
No of Figures: 58

Europe Vaccines Market, By Composition (Combination Vaccines, Mono Vaccines), Type (Subunit, Recombinant, Polysaccharide and Conjugate Vaccines, Live-Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, DNA Vaccines), Kind (Routine Vaccine, Recommended Vaccine, Required Vaccine), Age of Administration (Pediatric Vaccine, Adult Vaccine), Diseases (Pneumococcal Disease, Measles, Mumps & Varicella, DPT, Hepatitis, Influenza, Typhoid, Meningococcal, Rabies, Japanese Encephalitis, Yellow Fever, Others), Route of Administration (Injectable, Oral, Nasal), End User (Community Hospitals, Hospitals, Specialty Centres, Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland and Rest of Europe) Industry Trends and Forecast to 2028

Market Analysis and Insights: Europe Vaccines Market

Europe vaccines market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 6.5% in the forecast period of 2021 to 2028 and is expected to reach USD 61,988.47 million by 2028. High prevalence of chronic condition such as flu and bacterial infectious diseases and launch of newer vaccines are the major drivers which propelled the demand of the market in the forecast period.

Vaccines comprises features such increasing need for safe and effective product will impact in launching new product by the manufactures into the market which enhance its demand as well as increasing investment in research and development leads to the market growth. Currently various research studies are taking place which is expected to create a competitive advantage for manufacturers to develop new and innovative vaccines products which is expected to provide various other opportunities in the vaccines market. However, difficulties associated with transport and production of vaccines and fear among patients related to injections and needle sticks expected to restraint the market growth in the forecast period.

Vaccines are the biological preparation that provides active acquired immunity against a particular disease. Vaccine contains a substance or agents that resembles like a disease causing microorganisms and is prepared by weekend or killed form of pathogens like bacteria or virus. When weakened or killed pathogens are injected in a body these microbes causes B cells that are memory cells of immune system to recognize the pathogen and in future if same pathogen attacks the body it works against those. Vaccines have been discovered for several kind of infectious disease prevailing around including pneumococcal disease, measles, mumps, rubella, hepatitis, influenza, typhoid, varicella, rabies, among others.

The vaccines market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Vaccines Market Scope and Market Size

The vaccines market is categorized into eight notable segments which are based on the composition, type, kind, age of administration, diseases, route of administration, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

On the basis of composition, the vaccines market is segmented into combination vaccines, monovaccines. In 2021, combination vaccines segment is dominating the market because a single combination vaccine can be used for prevention of different kinds of disease.
On the basis of type, the vaccines market is segmented into subunit, recombinant, polysaccharide and conjugate vaccines, live-attenuated vaccines, inactivated vaccines, toxoid vaccines and DNA vaccines. In 2021, subunit, recombinant, polysaccharide and conjugate vaccine segment is dominating the market because these vaccines can be used for almost everyone so as to enhance the immune response. Moreover, rising company investments and increasing government support for development of novel vaccine is acting as another factor for accelerating the market growth.
On the basis of kind, the vaccines market is segmented into routine vaccine, recommended vaccine and required vaccine. In 2021, routine vaccine segment is dominating the market because healthcare professional and government authorities are highly focused on childhood vaccination so as to break the intergenerational cycle of poverty.
On the basis of age of administration, the vaccines market is segmented into pediatric vaccine and adult vaccine. In 2021, pediatric vaccine segment is dominating the market because of increasing launch of immunization program and campaign for childhood vaccination.
On the basis of diseases, the vaccines market is segmented into pneumococcal disease, measles, mumps & varicella, DPT, hepatitis, influenza, typhoid, meningococcal, rabies, Japanese encephalitis, yellow fever and others. In 2021, pneumococcal disease segment is dominating the market because of rising prevalence on pneumonia infection, more common in children and also reported to affect large population of adults.
On the basis of route of administration, the vaccines market is segmented into injectable, oral and nasal. In 2021, injectable segment is dominating the market because vaccines administered via parenteral route provide long term systemic response in a controlled release manner.
On the basis of end user, the vaccines market is segmented into community hospitals, hospitals, specialty centres, clinics and others. In 2021, community hospitals segment is dominating the market because of increasing government focus on vaccination and increasing campaign launch for mass vaccination.
On the basis of distribution channel, the vaccines market is segmented into hospital pharmacy, retail pharmacy and online pharmacy. In 2021, hospital pharmacy segment is dominating the market because most of the people visit community hospitals and hospital who used to procure vaccines directly from nearby hospital pharmacy.

Vaccines Market Country Level Analysis

The vaccines market is analyzed and market size information is provided on the basis of the composition, type, kind, age of administration, diseases, route of administration, end user and distribution channel.

The countries covered in the vaccines market report are Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland and Rest of Europe.

Routine vaccine segment in Europe region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because of increasing clinical trials and research development for prevention of flu related diseases among the children. Germany is leading the growth of the Asia-Pacific market and routine vaccine segment is dominating in this country due to increased consumption and production of vaccines. U.K. is the fastest growing country because rising government initiative for the vaccination.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Presence of Pipeline Products and Increasing Awareness for Vaccination are Boosting the Market Growth of Vaccines

Vaccines market also provides you with detailed market analysis for every country growth in Vaccines industry with Vaccines drugs sales, impact of advancement in the Vaccines technology and changes in regulatory scenarios with their support for the Vaccines market. The data is available for historic period 2010 to 2019.

Competitive Landscape and Vaccines Market Share Analysis

Vaccines market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to Vaccines market.

The major companies which are dealing in the vaccines are Emergent BioSolutions Inc., Dynavax Technologies, Valneva SE, Bavarian Nordic, Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.), Takeda Pharmaceutical Company Limited, Seqirus (A Subsidiary of CSL Limited), Abbott, AstraZeneca, Sanofi, Pfizer Inc., Janssen Global Services, LLC (A Subsidiary of Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd, DAIICHI SANKYO COMPANY, LIMITED, ALK, Panacea Biotec Ltd, BAXTER VACCINES (A Subsidiary of Baxter), GlaxoSmithKline plc., Serum Institute of India Pvt., among others.

Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the vaccines market.

In August 2020, Bavarian Nordic launched RABAVERT vaccine in U.S. Along with this the company boosted the vaccine distribution and marketing capabilities. RABAVERT vaccine is indicated for vaccination of all age population. This initiative helped the company to attain a lucrative growth in vaccines market.
In July 2020, Dynavax Technologies collaborated with Mount Sinai for development of universal influenza vaccine. As per the collaboration the Mount Sinai will use the CpG adjuvant manufactured by Dynavax Technologies Corporation for novel vaccine development. For the new vaccine development Mount Sinai will produce chimeric hemagglutinin (cHA) designed to protect against all different strains of influenza. This initiative boosted the company’s revenue by providing its proprietary platform for novel vaccine development

Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market player is enhancing the company market in the Vaccines market which also provides the benefit for organization to improve their offering for Vaccines.

SKU-59877

LIST OF TABLES

TABLE 1 EUROPE VACCINES MARKET, PIPELINE ANALYSIS

TABLE 2 REGULATIONS IMPOSED BY SEVERAL REGULATORY AGENCIES IN DIFFERENT REGIONS

TABLE 3 RECOMMENDED TEMPERATURE AND STORAGE LENGTH AT VARIOUS LEVEL OF THE COLD CHAIN.

TABLE 4 PROCEDURES FOR REPORTING TO UNICEF VACCINE ARRIVALS.

TABLE 5 LOGISITCS PROCESS ACORSS DIFFERENT REGIONS.

TABLE 6 THE U.S. FUNDING FOR GAVI (2015-2019)

TABLE 7 PRICE OF THE VACCINES BETWEEN THE U.S. AND DEVELOPING COUNTRIES

TABLE 8 VACCINES UNDER CLINICAL TRIAL

TABLE 9 THE SIDE EFFECTS RELATED TO THE VACCINES

TABLE 10 INCREASE IN OPERATIONAL COST COMPONENTS DUE TO COVID-19

TABLE 11 TOTAL NUMBER OF CASES FOR MEASLES REPORTED BY THE TEN COUNTRIES

TABLE 12 EUROPE VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)

TABLE 13 EUROPE COMBINATION VACCINES IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 14 EUROPE MONO VACCINES IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 15 EUROPE VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 16 EUROPE SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 17 EUROPE LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 18 EUROPE LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 19 EUROPE INACTIVATED VACCINES IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 20 EUROPE INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 21 EUROPE TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 22 EUROPE TOXOID VACCINES IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 23 EUROPE VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 24 EUROPE ROUTINE VACCINE IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 25 EUROPE ROUTINE VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 26 EUROPE RECOMMENDED VACCINE IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 27 EUROPE RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 28 EUROPE REQUIRED VACCINE IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 29 EUROPE REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 30 EUROPE VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 31 EUROPE PEDIATRIC VACCINE IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 32 EUROPE PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 33 EUROPE ADULT VACCINE IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 34 EUROPE ADULT IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 35 EUROPE PNEUMOCOCCAL DISEASE IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 36 EUROPE MEASLES, MUMPS & RUBELLA IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 37 EUROPE DPT IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 38 EUROPE HEPATITIS IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 39 EUROPE INFLUENZA IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 40 EUROPE TYPHOID IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 41 EUROPE MENINGOCOCCAL IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 42 EUROPE VARICELLA IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 43 EUROPE RABIES IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 44 EUROPE JAPANESE ENCEPHALITIS IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 45 EUROPE YELLOW FEVER IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 46 EUROPE OTHER IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 47 EUROPE VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 48 EUROPE INJECTABLE IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 49 EUROPE INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 50 EUROPE ORAL IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 51 EUROPE NASAL IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 52 EUROPE VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 53 EUROPE COMMUNITY HOSPITALS IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 54 EUROPE HOSPITALS IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 55 EUROPE SPECIALTY CENTRES IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 56 EUROPE CLINICS IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 57 EUROPE OTHERS IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 58 EUROPE VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 59 EUROPE HOSPITAL PHARMACY IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 60 EUROPE RETAIL PHARMACY IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 61 EUROPE ONLINE PHARMACY IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 62 EUROPE VACCINES MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 63 EUROPE VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)

TABLE 64 EUROPE VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 65 EUROPE SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 66 EUROPE LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 67 EUROPE INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 68 EUROPE TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 69 EUROPE VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 70 EUROPE ROUTINE VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 71 EUROPE RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 72 EUROPE REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 73 EUROPE VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 74 EUROPE PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 75 EUROPE ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 76 EUROPE VACCINES MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 77 EUROPE VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 78 EUROPE INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 79 EUROPE VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 80 EUROPE VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 81 GERMANY VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)

TABLE 82 GERMANY VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 83 GERMANY SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 84 GERMANY LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 85 GERMANY INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 86 GERMANY TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 87 GERMANY VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 88 GERMANY ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 89 GERMANY RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 90 GERMANY REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 91 GERMANY VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 92 GERMANY PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 93 GERMANY ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 94 GERMANY VACCINES MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 95 GERMANY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 96 GERMANY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 97 GERMANY VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 98 GERMANY INJECTABLE IN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 99 FRANCE VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)

TABLE 100 FRANCE VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 101 FRANCE SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 102 FRANCE LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 103 FRANCE INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 104 FRANCE TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 105 FRANCE VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 106 FRANCE ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 107 FRANCE RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 108 FRANCE REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 109 FRANCE VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 110 FRANCE PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 111 FRANCE ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 112 FRANCE VACCINES MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 113 FRANCE VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 114 FRANCE INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 115 FRANCE VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 116 FRANCE VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 117 U.K. VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)

TABLE 118 U.K. VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 119 U.K. SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 120 U.K. LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 121 U.K. INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 122 U.K. TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 123 U.K. VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 124 U.K. ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 125 U.K. RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 126 U.K. REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 127 U.K. VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 128 U.K. PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 129 U.K. ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 130 U.K. VACCINES MARKET, BY DISEASES, 2019-2028 (USD MILLION)

TABLE 131 U.K. VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 132 U.K. INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 133 U.K. VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 134 U.K. VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 135 ITALY VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)

TABLE 136 ITALY VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 137 ITALY SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 138 ITALY LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 139 ITALY INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 140 ITALY TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 141 ITALY VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 142 ITALY ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 143 ITALY RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 144 ITALY REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 145 ITALY VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 146 ITALY PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 147 ITALY ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 148 ITALY VACCINES MARKET, BY DISEASES, 2019-2028 (USD MILLION)

TABLE 149 ITALY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 150 ITALY INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 151 ITALY VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 152 ITALY VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 153 SPAIN VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)

TABLE 154 SPAIN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 155 SPAIN SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 156 SPAIN LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 157 SPAIN INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 158 SPAIN TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 159 SPAIN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 160 SPAIN ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 161 SPAIN RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 162 SPAIN REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 163 SPAIN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 164 SPAIN PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 165 SPAIN ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 166 SPAIN VACCINES MARKET, BY DISEASES, 2019-2028 (USD MILLION)

TABLE 167 SPAIN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 168 SPAIN INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 169 SPAIN VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 170 SPAIN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 171 NETHERLAND VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)

TABLE 172 NETHERLAND VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 173 NETHERLAND SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 174 NETHERLAND LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 175 NETHERLAND INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 176 NETHERLAND TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 177 NETHERLAND VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 178 NETHERLAND ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 179 NETHERLAND RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 180 NETHERLAND REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 181 NETHERLAND VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 182 NETHERLAND PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 183 NETHERLAND ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 184 NETHERLAND VACCINES MARKET, BY DISEASES, 2019-2028 (USD MILLION)

TABLE 185 NETHERLAND VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 186 NETHERLAND INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 187 NETHERLAND VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 188 NETHERLAND VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 189 RUSSIA VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)

TABLE 190 RUSSIA VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 191 RUSSIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 192 RUSSIA LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 193 RUSSIA INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 194 RUSSIA TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 195 RUSSIA VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 196 RUSSIA ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 197 RUSSIA RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 198 RUSSIA REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 199 RUSSIA VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 200 RUSSIA PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 201 RUSSIA ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 202 RUSSIA VACCINES MARKET, BY DISEASES, 2019-2028 (USD MILLION)

TABLE 203 RUSSIA VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 204 RUSSIA INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 205 RUSSIA VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 206 RUSSIA VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 207 SWITZERLAND VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)

TABLE 208 SWITZERLAND VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 209 SWITZERLAND SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 210 SWITZERLAND LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 211 SWITZERLAND INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 212 SWITZERLAND TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 213 SWITZERLAND VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 214 SWITZERLAND ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 215 SWITZERLAND RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 216 SWITZERLAND REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 217 SWITZERLAND VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 218 SWITZERLAND PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 219 SWITZERLAND ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 220 SWITZERLAND VACCINES MARKET, BY DISEASES, 2019-2028 (USD MILLION)

TABLE 221 SWITZERLAND VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 222 SWITZERLAND INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 223 SWITZERLAND VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 224 SWITZERLAND VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 225 TURKEY VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)

TABLE 226 TURKEY VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 227 TURKEY SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 228 TURKEY LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 229 TURKEY INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 230 TURKEY TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 231 TURKEY VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 232 TURKEY ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 233 TURKEY RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 234 TURKEY REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 235 TURKEY VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 236 TURKEY PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 237 TURKEY ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 238 TURKEY VACCINES MARKET, BY DISEASES, 2019-2028 (USD MILLION)

TABLE 239 TURKEY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 240 TURKEY INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 241 TURKEY VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 242 TURKEY VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 243 AUSTRIA VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)

TABLE 244 AUSTRIA VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 245 AUSTRIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 246 AUSTRIA LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 247 AUSTRIA INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 248 AUSTRIA TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 249 AUSTRIA VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 250 AUSTRIA ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 251 AUSTRIA RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 252 AUSTRIA REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 253 AUSTRIA VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 254 AUSTRIA PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 255 AUSTRIA ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 256 AUSTRIA VACCINES MARKET, BY DISEASES, 2019-2028 (USD MILLION)

TABLE 257 AUSTRIA VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 258 AUSTRIA INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 259 AUSTRIA VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 260 AUSTRIA VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 261 NORWAY VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)

TABLE 262 NORWAY VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 263 NORWAY SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 264 NORWAY LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 265 NORWAY INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 266 NORWAY TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 267 NORWAY VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 268 NORWAY ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 269 NORWAY RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 270 NORWAY REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 271 NORWAY VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 272 NORWAY PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 273 NORWAY ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 274 NORWAY VACCINES MARKET, BY DISEASES, 2019-2028 (USD MILLION)

TABLE 275 NORWAY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 276 NORWAY INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 277 NORWAY VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 278 NORWAY VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 279 HUNGARY VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)

TABLE 280 HUNGARY VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 281 HUNGARY SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 282 HUNGARY LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 283 HUNGARY INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 284 HUNGARY TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 285 HUNGARY VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 286 HUNGARY ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 287 HUNGARY RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 288 HUNGARY REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 289 HUNGARY VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 290 HUNGARY PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 291 HUNGARY ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 292 HUNGARY VACCINES MARKET, BY DISEASES, 2019-2028 (USD MILLION)

TABLE 293 HUNGARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 294 HUNGARY INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 295 HUNGARY VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 296 HUNGARY VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 297 LITHUANIA VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)

TABLE 298 LITHUANIA VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 299 LITHUANIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 300 LITHUANIA LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 301 LITHUANIA INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 302 LITHUANIA TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 303 LITHUANIA VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 304 LITHUANIA ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 305 LITHUANIA RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 306 LITHUANIA REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 307 LITHUANIA VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 308 LITHUANIA PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 309 LITHUANIA ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 310 LITHUANIA VACCINES MARKET, BY DISEASES, 2019-2028 (USD MILLION)

TABLE 311 LITHUANIA VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 312 LITHUANIA INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 313 LITHUANIA VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 314 LITHUANIA VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 315 IRELAND VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)

TABLE 316 IRELAND VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 317 IRELAND SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 318 IRELAND LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 319 IRELAND INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 320 IRELAND TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 321 IRELAND VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 322 IRELAND ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 323 IRELAND RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 324 IRELAND REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 325 IRELAND VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 326 IRELAND PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 327 IRELAND ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 328 IRELAND VACCINES MARKET, BY DISEASES, 2019-2028 (USD MILLION)

TABLE 329 IRELAND VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 330 IRELAND INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 331 IRELAND VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 332 IRELAND VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 333 POLAND VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)

TABLE 334 POLAND VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 335 POLAND SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 336 POLAND LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 337 POLAND INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 338 POLAND TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 339 POLAND VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 340 POLAND ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 341 POLAND RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 342 POLAND REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)

TABLE 343 POLAND VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 344 POLAND PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 345 POLAND ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 346 POLAND VACCINES MARKET, BY DISEASES, 2019-2028 (USD MILLION)

TABLE 347 POLAND VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 348 POLAND INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 349 POLAND VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 350 POLAND VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 351 REST OF EUROPE VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

BROWSE RELATED Press Release

Empowering Global Health: The Rising Tide of Vaccines - Fortifying Communities, Saving Lives, and Building a Resilient Future Together

Growing Immunization Programs and Campaigns drive the Growth of the Asia-Pacific Vaccines Market

Growing Immunization Programs and Campaigns are driving the Growth of Middle East and Africa Animal and Human Vaccines Market

Free Sample Report

CHOOSE LICENCE TYPE

Enterprise User 4200.00
Single User 3500.00
DBMR Factbook 2000.00
DBMR Prime 5500.00
DBMR Supreme 7500.00

Buy Now

Request for TOC Speak to Analyst Inquire Before Buying Free Sample Report

Advance Formative Research Customization Request for bulk Reports

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Pharmaceutical

Europe Vaccines Market – Industry Trends and Forecast to 2028

Market Analysis and Insights: Europe Vaccines Market

Global Vaccines Market Scope and Market Size

Vaccines Market Country Level Analysis

Competitive Landscape and Vaccines Market Share Analysis

Please fill in the below form for Infographics

Research Methodology:

Please fill in the below form for Research Methodology

Customization Available:

Please fill in the below form for Available Customization

BROWSE RELATED Press Release

CHOOSE LICENCE TYPE

Why Choose Us

Industry Coverage

Regional Coverage

Technology Coverage

Goal Oriented Solutions

Unparallel Analyst Support

Client Testimonials

David Manning - Thermo Fisher Scientific

Manager - Market Analytics,

Business Development Manager,

Business Intelligence and Analytics,

Competition Analyst,

Marketing Director,

COO,

Marketing Director,

Product manager,

Investor relations,

Market Analyst,

Andrew - Senior Global Marketing Manager,

Amarildo - Manager, Global Strategic Alignment

Tor Hammer

Tommaso Finocchiaro

Yuki Kopyl (Asian Business Development Department)

Reports

Market Insights

Support

Solutions

Pharmaceutical

Europe Vaccines Market – Industry Trends and Forecast to 2028

Market Analysis and Insights: Europe Vaccines Market

Global Vaccines Market Scope and Market Size

Vaccines Market Country Level Analysis

Competitive Landscape and Vaccines Market Share Analysis

Please fill in the below form for Infographics

Research Methodology:

Please fill in the below form for Research Methodology

Customization Available:

Please fill in the below form for Available Customization

BROWSE RELATED REPORTS

BROWSE RELATED Blogs

BROWSE RELATED Press Release

CHOOSE LICENCE TYPE

Why Choose Us

Industry Coverage

Regional Coverage

Technology Coverage

Goal Oriented Solutions

Unparallel Analyst Support

Client Testimonials

David Manning - Thermo Fisher Scientific

Manager - Market Analytics,

Business Development Manager,

Business Intelligence and Analytics,

Competition Analyst,

Marketing Director,

COO,

Marketing Director,

Product manager,

Investor relations,

Market Analyst,

Andrew - Senior Global Marketing Manager,

Amarildo - Manager, Global Strategic Alignment

Tor Hammer

Tommaso Finocchiaro

Yuki Kopyl (Asian Business Development Department)

Share Your Experience With Us

Share Your
Experience With Us